請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19113
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林淑文 | |
dc.contributor.author | Tong-Ling Chien | en |
dc.contributor.author | 簡彤凌 | zh_TW |
dc.date.accessioned | 2021-06-08T01:45:29Z | - |
dc.date.copyright | 2016-08-26 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-08-12 | |
dc.identifier.citation | 1. McCloskey RV. Spontaneous reports of bleeding: comparison of N-methylthiotetrazole side chain (MTT) and non-MTT cephalosporins. J Infect Dis 1988;158:1405.
2. Hicks MJ, Flaitz CM. The role of antibiotics in platelet dysfunction and coagulopathy. Int J Antimicrob Agents 1993;2:129-49. 3. Andes D, Craig W. Cephalosporins. In: Mandell G, Bennett J, Dolin R, eds. Mandell: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 8th ed. Philadelphia: Churchill Livingstone; 2015:278-92. 4. Neu HC. Structure-activity relations of new beta-lactam compounds and in vitro activity against common bacteria [with discussion]. Rev Infect Dis 1983;5:S319-S37. 5. Neu HC. beta-Lactam antibiotics: structural relationships affecting in vitro activity and pharmacologic properties. Rev Infect Dis 1986;8 Suppl 3:S237-59. 6. Ruckdeschel G, Eder W. Comparative in vitro activity of the new oxacephem antibiotic, flomoxef (6315-S). Eur J Clin Microbiol Infect Dis 1988;7:687-91. 7. Griffith DL, Novak E, Greenwald CA, Metzler CM, Paxton LM. Clinical experience with cefmetazole sodium in the United States: an overview. J Antimicrob Chemother 1989;23 Suppl D:21-33. 8. Norrby SR. Adverse reactions and interactions with newer cephalosporin and cephamycin antibiotics. Med Toxicol 1986;1:32-46. 9. Uchida K, Matsubara T. Effect of flomoxef on blood coagulation and alcohol metabolism. Infection 1991;19 Suppl 5:S284-95. 10. Nichols RL, Wikler MA, McDevitt JT, Lentnek AL, Hosutt JA. Coagulopathy associated with extended-spectrum cephalosporins in patients with serious infections. Antimicrob Agents Chemother 1987;31:281-5. 11. Rupp ME, Fey PD. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs 2003;63:353-65. 12. Neu HC. The in vitro activity, human pharmacology, and clinical effectiveness of new beta-lactam antibiotics. Annu Rev Pharmacol Toxicol 1982;22:599-642. 13. Buening MK, Wold JS, Israel KS, Krammer RB. Disulfiram-like reaction to beta-lactams. JAMA 1981;245:2027. 14. Lerner PI, Lubin A. Letter: Coagulopathy with cefazolin in uremia. N Engl J Med 1974;290:1324. 15. Wurtz RM, Sande MA. Cefotetan and coagulopathy. J Infect Dis 1989;160:555-6. 16. Freedy HR, Jr., Cetnarowski AB, Lumish RM, Schafer FJ. Cefoperazone-induced coagulopathy. Drug Intell Clin Pharm 1986;20:281-3. 17. Parker SW, Baxter J, Beam TR, Jr. Cefoperazone-induced coagulopathy. Lancet 1984;1:1016. 18. Fainstein V, Bodey GP, McCredie KB, et al. Coagulation abnormalities induced by beta-lactam antibiotics in cancer patients. J Infect Dis 1983;148:745-50. 19. Bang NU, Kammer RB. Hematologic complications associated with beta-lactam antibiotics. Rev Infect Dis 1983;5:S380-S93. 20. Hochman R, Clark J, Rolla A, Thomas S, Kaldany A, D'Elia JA. Bleeding in patients with infections. Are antibiotics helping or hurting? Arch Intern Med 1982;142:1440-2. 21. Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA. Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan. Arch Surg 1991;126:524-5. 22. Mueller RJ, Green D, Phair JP. Hypoprothrombinemia associated with cefoperazone therapy. South Med J 1987;80:1360-2. 23. Stork C, Etzel JV, Brocavich JM, Forlenza S. Cephalosporin-associated hypoprothrombinemia case and review of literature. Journal of Pharmacy Technology 1994;10:5-13. 24. Wong RSM, Cheng G, Chan NPH, Wong WS, Ng MHL. Use of cefoperazone still needs a caution for bleeding from induced vitamin K deficiency. Am J Hematol 2006;81:76-. 25. Shevchuk YM, Conly JM. Antibiotic-associated hypoprothrombinemia: a review of prospective studies, 1966-1988. Rev Infect Dis 1990;12:1109-26. 26. Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M. Enhanced bleeding with cefoxitin or moxalactam - statistical-analysis within a defined population of 1493 patients. Arch Intern Med 1986;146:2159-64. 27. Pakter RL, Russell TR, Mielke CH, West D. Coagulopathy associated with the use of moxalactam. Jama-Journal of the American Medical Association 1982;248:1100-. 28. Hooper CA, Haney BB, Stone HH. Gastrointestinal-bleeding due to vitamin-K deficiency in patients on parenteral cefamandole. Lancet 1980;1:39-40. 29. Cooke G BJ, Costello M. Newly identified vitamin K-producing bacteria isolated from the neonatal faecal flora. Microb Ecol Health Dis 2006;18:133-8. 30. Lipsky JJ. N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia. Lancet 1983;2:192-3. 31. Uotila L, Suttie JW. Inhibition of vitamin K-dependent carboxylase in vitro by cefamandole and its structural analogs. J Infect Dis 1983;148:571-8. 32. Bechtold H, Andrassy K, Jahnchen E, et al. Evidence for impaired hepatic vitamin K1 metabolism in patients treated with N-methyl-thiotetrazole cephalosporins. Thromb Haemost 1984;51:358-61. 33. Ingalls CS, Freimer EH. Detection of antibiotic-induced platelet dysfunction in whole-blood using flow-cytometry. J Antimicrob Chemother 1992;29:313-21. 34. Stafford D. The vitamin K cycle. J Thromb Haemost 2005;3:1873-8. 35. Hill MJ. Intestinal flora and endogenous vitamin synthesis. Eur J Cancer Prev 1997;6 Suppl 1:S43-5. 36. Shearer MJ, Bechtold H, Andrassy K, et al. Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status. J Clin Pharmacol 1988;28:88-95. 37. Agnelli G, Delfavero A, Parise P, et al. Cephalosporin-induced hypoprothrombinemia - Is the N-Methylthiotetrazole side-chain the culprit. Antimicrob Agents Chemother 1986;29:1108-9. 38. Lipsky JJ. Mechanism of the inhibition of the gamma-carboxylation of glutamic acid by N-methylthiotetrazole-containing antibiotics. Proc Natl Acad Sci U S A 1984;81:2893-7. 39. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991;30:10363-70. 40. Bennett NT, Schultz GS. Growth-factors and wound-healing - biochemical-properties of growth-factors and their receptors. Am J Surg 1993;165:728-37. 41. Lin PJ. Reviewing the reality: why we need to change. Eur Heart J Suppl 2005;7:E15-E20. 42. Wittkowsky AK. Warfarin. In: Dager WE GM, Nutescu EA, ed. Anticoagulation Therapy: A Point-of-Care Guide. Bethesda, Maryland: American Society of Health-System Pharmacists; 2011:12. 43. Hirsh J, Poller L. The international normalized ratio. A guide to understanding and correcting its problems. Arch Intern Med 1994;154:282-8. 44. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:401S-28S. 45. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119:8S-21S. 46. Conly JM, Ramotar K, Chubb H, Bow EJ, Louie TJ. Hypoprothrombinemia in febrile, neutropenic patients with cancer: association with antimicrobial suppression of intestinal microflora. J Infect Dis 1984;150:202-12. 47. Aronoff GR, Wolen RL, Obermeyer BD, Black HR. Pharmacokinetics and protein binding of cefamandole and its 1-methyl-1 H-tetrazole-5-thiol side chain in subjects with normal and impaired renal function. J Infect Dis 1986;153:1069-74. 48. Barza M, Furie B, Brown AE, Furie BC. Defects in vitamin K-dependent carboxylation associated with moxalactam treatment. J Infect Dis 1986;153:1166-9. 49. Bang NU, Tessler SS, Heidenreich RO, Marks CA, Mattler LE. Effects of moxalactam on blood coagulation and platelet function. Rev Infect Dis 1982;4 Suppl:S546-54. 50. Sattler FR, Weitekamp MR, Sayegh A, Ballard JO. Impaired hemostasis caused by beta-lactam antibiotics. Am J Surg 1988;155:30-9. 51. Goss TF, Walawander CA, Grasela TH, Jr., Meisel S, Katona B, Jaynes K. Prospective evaluation of risk factors for antibiotic-associated bleeding in critically ill patients. Pharmacotherapy 1992;12:283-91. 52. Baxter JG, Marble DA, Whitfield LR, Wels PB, Walczak P, Schentag JJ. Clinical risk factors for prolonged PT/PTT in abdominal sepsis patients treated with moxalactam or tobramycin plus clindamycin. Ann Surg 1985;201:96-102. 53. Strom BL, Schinnar R, Gibson GA, Brennan PJ, Berlin JA. Risk of bleeding and hypoprothrombinaemia associated with NMTT side chain antibiotics: Using cefoperazone as a test case. Pharmacoepidemiol Drug Saf 1999;8:81-94. 54. Breen GA, St Peter WL. Hypoprothrombinemia associated with cefmetazole. Ann Pharmacother 1997;31:180-4. 55. Bertino JS, Kozak AJ, Reese RE, Chiarello LA. Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital. Arch Intern Med 1986;146:1125-8. 56. Chen L-J, Hsiao F-Y, Lin S-W. Use of hypoprothrombinemia-inducing cephalosporins and the risk of hemorrhagic events: a nationwide nested case-control study. PLoS One (accepted). 57. 董曼翎. 以回溯性世代研究探討Cephamycin類抗生素造成低凝血酶原血症與出血風險. 2015. 58. Sullivan LM, Massaro JM, D'Agostmo RB. Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med 2004;23:1631-60. 59. Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating: Springer Science & Business Media; 2008. 60. Han K, Song K, Choi BW. How to Develop, Validate, and Compare Clinical Prediction Models Involving Radiological Parameters: Study Design and Statistical Methods. Korean Journal of Radiology 2016;17:339-50. 61. 衛生福利部中央健康保險署-全球資訊網. (Accessed Jan. 10, 2016, at http://www.nhi.gov.tw/.) 62. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9. 63. 台大醫院藥劑部. 抗凝血門診口服抗凝血藥品warfarin建議使用準則. 2013. 64. 臺大醫院藥劑部電子處方集. (Accessed Feb. 27, 2016, at http://140.112.125.99/phar/intranet/druginfo/index.asp/.) 65. Cefmetazole. In:DRUGDEX System (Micromedex 2.0). Greenwood Village, CO: Truven Health Analytics; c1974-2016. http://www.micromedexsolutions.com/micromedex2/librarian. Accessed June 26, 2016. 66. Flomoxef. In:DRUGDEX System (Micromedex 2.0). Greenwood Village, CO: Truven Health Analytics; c1974-2016. http://www.micromedexsolutions.com/micromedex2/librarian. Accessed June 26, 2016. 67. Cefoxitin. In:DRUGDEX System (Micromedex 2.0). Greenwood Village, CO: Truven Health Analytics; c1974-2016. http://www.micromedexsolutions.com/micromedex2/librarian. Accessed June 26, 2016. 68. Cefoperazone. In:DRUGDEX System (Micromedex 2.0). Greenwood Village, CO: Truven Health Analytics; c1974-2016. http://www.micromedexsolutions.com/micromedex2/librarian. Accessed June 26, 2016. 69. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med 2008;3:17. 70. Pavlou M, Ambler G, Seaman SR, et al. How to develop a more accurate risk prediction model when there are few events. BMJ 2015;351:h3868. 71. Chan P-C, Shinn-Forng Peng S, Chiou M-Y, et al. Risk for tuberculosis in child contacts. Development and validation of a predictive score. Am J Respir Crit Care Med 2014;189:203-13. 72. Lipsky BA, Weigelt JA, Sun XW, Johannes RS, Derby KG, Tabak YP. Developing and validating a risk score for lower-extremity amputation in patients hospitalized for a diabetic foot infection. Diabetes Care 2011;34:1695-700. 73. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902-7. 74. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004;44:1393-9. 75. Lee MH, Lu SN, Yuan Y, et al. Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. PLoS One 2014;9:e94760. 76. Hung YC, Lin CL, Liu CJ, et al. Development of risk scoring system for stratifying population for hepatocellular carcinoma screening. Hepatology 2015;61:1934-44. 77. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med 2000;19:453-73. 78. David W. Hosmer J, Lemeshow S, Sturdivant RX. Assessing the Fit of the Model. In: Applied Logistic Regression. 3rd ed. New Jersey: John Wiley & Sons, Inc.; 2013:153-225. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19113 | - |
dc.description.abstract | Background:
Cephamycins are a group of unique cephalosporins in perspective of the substitution group at 7α of the cephem structure. The difference in chemical structure expanded their spectrum of activity and enabled cephamycins a popular choice among prescribers. With the surged amount of prescriptions, a growing number of suspected cephamycin-associated hemorrhagic events were reported, which raised the attention of the public. Several studies had proposed possible attributable mechanisms and attempted to identify risk factors for the adverse events. The diminished production of vitamin K by intestinal microflora resulted from the eradication by cephamycins and the inactivation of the coagulation factors due to impaired vitamin K cycle interfered by N-methylthiotetrazole (NMTT) leaving group of cephamycins are the two most convincible hypotheses for hemorrhagic outcomes to date. Other risk factors including malnutrition, advanced age, and renal/hepatic dysfunction were also suggested. Recent studies using National Health Insurance Research Database (NHIRD) and database of a teaching hospital in Taipei had tried identifying the risk factors, but the NHIRD was lack of laboratory information, and insufficient number of users of cephamycins were identified by the other study. The mentioned limitations urged us to conduct this research using National Taiwan University Hospital (NTUH) electronic medical records to determine risk factors for cephamycin-associated hemorrhagic events and further produce a prediction risk scoring system for clinical pharmacists to use and to enhance the quality of care as our ultimate goal. Methods: Adults at least 20 years old and consecutively used study antibiotics (cefmetazole, flomoxef, cefoxitin, cefoperazone as cephamycins; amoxicillin/clavulanic acid, ampicillin/sulbactam, cefuroxime, cefotaxime, ceftriaxone as reference) for more than 48 hours at the emergency/inpatient departments of NTUH during January 1st, 2009 to December 31st, 2015 were included for observation of any hemorrhagic events occurred during the following ten days since the initiation of study antibiotics (index date). The population was separated into two cohorts by the end of 2013 for evaluation of risk factors (2009-2013 cohorts) and validation of the established scoring system using the identified risk factors (2014-2015 cohort). Univariate logistic regression was adapted for assessment of the crude association between factors and the outcome of interest. Multivariate logistic regression was used for the adjusted association. Results of the multivariate logistic regression were treated as the foundation to develop the risk scoring system. Both cohorts contributed in the validation of the scoring system. Results: There were 46402 (contributed from 37094 individuals) and 22681 episodes (from 19201 individuals) identified at 2009-2013 and 2014-2015 cohorts, respectively. The 2009-2013 cohort had 18821 episodes of cephamycins and 27581 episodes of reference antibiotics, with 227 and 129 hemorrhagic events among respective study groups. The 2014-2015 cohort had 8615 episodes of cephamycins and 14066 episodes of reference antibiotics, with 116 and 88 hemorrhagic events among respective study groups. Gastrointestinal bleeding was the majority of the events across both cohorts (85.11% vs. 95.10%). Use of cephamycins was associated with a higher risk for hemorrhagic outcomes (aOR 2.03, 95% CI 1.60-2.58). Other risk factors including chronic hepatic disease (aOR 2.08, 95% CI 1.54-2.81), at least 65 years old (aOR 1.66, 95% CI 1.31-2.09), prominent bleeding tendency (aOR 2.46, 95% CI 1.94-3.12), and bleeding history within previous 180 days of the index date (aOR 6.84, 95% CI 5.38-8.68). A nine-score risk scoring system (AUROC=0.8035, 95% CI 0.7794-0.8275; Hosmer-Lemeshow goodness-of-fit test p=0.1044) named CHABB was developed based on the identified risk factors (1, 1, 1, 2, 4 points for each item), with higher scores indicating higher risk for bleeding. Conclusion: Use of cephamycins was associated with higher hemorrhagic events compared with commonly used penicillins and cephalosporins. The established risk scoring system, CHABB, may help clinical pharmacists identify high-risk patients, provide recommendations and monitor adverse events in cephamycins users according to the predictive risk for developing hemorrhagic events, and eventually enhancing the overall quality of care. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T01:45:29Z (GMT). No. of bitstreams: 1 ntu-105-R03451004-1.pdf: 2243560 bytes, checksum: 3fbc97ab9590dc16fa78061e16c33b19 (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | Acknowledgment ................................................................................................................ i
Chinese Abstract ............................................................................................................... ii Abstract .............................................................................................................................. v Contents ......................................................................................................................... viii List of Tables ..................................................................................................................... x List of Figures ..................................................................................................................xii Chapter 1 Introduction .................................................................................................. 1 1.1 Overview ................................................................................................................. 1 1.2 Cephamycins Utilization in National Taiwan University Hospital .......................... 1 1.3 Study Objectives ...................................................................................................... 2 Chapter 2 Literature Review ......................................................................................... 3 2.1 Introduction to Cephamycins ................................................................................... 3 2.1.1 Molecular structures, spectrum of activity and clinical roles ............................. 3 2.1.2 Potential adverse effects of cephamycins .......................................................... 6 2.2 Mechanisms of Cephamycin-Induced Hypoprothrombinemia ................................. 6 2.3 Factors Predisposing to Cephamycin-Induced Hypoprothrombinemia and Hemorrhagic Events .....................................................................................................10 Chapter 3 Methods ...................................................................................................... 14 3.1 Data Source ............................................................................................................14 3.2 Study Design and Population ..................................................................................14 3.2.1 Inclusion/ Exclusion criteria for study population enrollment ..........................16 3.2.2 Study flow and aims .........................................................................................17 3.3 Measurements .........................................................................................................22 3.3.1 Index hospitalization ........................................................................................22 3.3.2 Treatment course and observational period ......................................................22 3.3.3 Study endpoints and history of hemorrhagic events .........................................22 3.3.4 Indications of antibiotics ..................................................................................24 3.3.5 Comorbid underlying diseases .........................................................................24 3.3.6 Abnormal laboratory results .............................................................................24 3.3.7 Concomitant antibiotics ...................................................................................31 3.3.8 Dose groups of cephamycins............................................................................31 3.4 Statistical Analysis .................................................................................................33 Chapter 4 Results ........................................................................................................ 34 4.1 Risk Factors for Cephamycin-Associated Hemorrhagic Events..............................36 4.2 Development and Validation of a Risk Scoring System for Cephamycin-Associated Hemorrhagic Events .....................................................................................................51 Chapter 5 Discussion ...................................................................................................75 5.1 Characteristics of Study Populations ......................................................................75 5.2 Discussion of Results by Aims ...............................................................................76 5.2.1 Risk factors for cephamycin-associated hemorrhagic events ...........................76 5.2.2 Development and validation of a risk scoring system for cephamycin-associated hemorrhagic events ..............................................................78 5.3 Attributable Proportion Among the Cephamycins Users ........................................80 5.4 Study Strengths and Limitations .............................................................................80 Chapter 6 Conclusion ..................................................................................................82 References ........................................................................................................................ 83 | |
dc.language.iso | en | |
dc.title | 建立和確效與cephamycin類抗生素相關出血事件之風險預測量表 | zh_TW |
dc.title | Development and Validation of a Risk Scoring System for Cephamycin-Associated Hemorrhagic Events | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 蕭斐元 | |
dc.contributor.oralexamcommittee | 方啟泰,溫有汶 | |
dc.subject.keyword | Cephamycin 類抗生素,出血,預測模型,風險分數,分數量表, | zh_TW |
dc.subject.keyword | cephamycin,hemorrhage,bleeding,prediction model,risk score,scoring system, | en |
dc.relation.page | 88 | |
dc.identifier.doi | 10.6342/NTU201602200 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2016-08-12 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 2.19 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。